Abstract
Introduction
 The underlying systematic review was conducted according to the PRISMA guidelines. [8]  Details on the underlying methodology of this systematic review are described in detail elsewhere [9] , hence below only a short description of the methodology is provided.  Eligible studies were decision models for full economic assessment in the context of the prevention and / or therapy of obesity.  Data Extraction: For each included study we extracted information on the external event validation approach, using the best practice recommendations of the report on "Model Transparency and Validation" issued by the ISPOR-SMDM Modeling Good Research Practices Task Force [6] .  This included information on the suitability of the external validation cohort (obesity cohort or other), on the systematic identification of suitable data sources, on the specification of dependence / independence of the used data sources (versus those used in the model simulations) and on the justification of the data source selection (due to predefined criteria).  Furthermore we extracted information on whether the external validation results were provided for each source separately, whether presentations of discrepancies (model vs. external validation) were provided, and whether qualitative measures on fit were provided.  Obesity is a multifactorial, chronic disorder that has, according to the World Health Organization (WHO), reached epidemic proportions globally and is a major contributor to the global burden of chronic disease and disability [1] .  The body mass index (BMI) is a simple index of weight-for-height that is commonly used to classify obesity in adults. It is defined as a person's weight in kilograms divided by the square of his height in meters (kg/m2). According to the WHO definition, a BMI ≥ 25 and < 30 is overweight; a BMI ≥30 is obesity [1] .  In 2014, worldwide, more than 1.9 billion adults (≈39%), 18 years and older, were overweight or obese. Of these, over 600 million adults (≈13%) were obese [2] . Overweight and obesity are leading risks for global deaths. In 2010, worldwide, it has been estimated that around 3.4 million adults died (≈6% of total deaths / year) as a result of being overweight or obese [3] .  In addition, 44% of diabetes cases, 23% of coronary heart disease cases and 7% to 41% of certain cancer cases are attributable to overweight and obesity [4] . A recently published systematic review has determined that this clinical burden of obesity is associated with a substantial economic burden, and that there is an urgent need for public health measures in order to save societal resources [5] .  Given this clinical and economic burden, it is of major interest for healthcare decision makers to identify effective and costeffective programs or interventions for obesity prevention and therapy.  Decision analytic modelling is particularly relevant in the case of prevention and therapy of obesity due to the chronic nature of the obesity associated morbidities (e.g. diabetes, coronary heart disease, stroke, osteoarthritis and specific cancer types) and the related mortality.  The core of each decision model is the clinical model structure; accordingly, the details on the specific event simulation approaches are of fundamental influence, as these have a central impact on all clinical, economic and patient outcomes simulated by a decision model. According to an up to date modelling guideline the models' accuracy of making relevant predictions should be investigated by performing specific validation procedures [6] .  In our study we focused on the external event validation procedures, that determine how good the modelling results do compare to external populations (e.g. long-term studies and/or real world observations), as those are of major interest for investigating the predictiveness of the event simulation approach.  Aim/Objective: Accordingly, the objective of our research was to determine and describe the related external validations of published health economic decision models in the context of obesity.  We set the focus on coronary heart disease (CHD), type 2 diabetes (T2D) and stroke. The rationale for this selection was that we have previously found that these events are most frequently simulated by published decision models [6] , and that cohort studies have demonstrated that these diseases are three of the most important consequences of obesity [7] .
Methods

Discussion
 Of 87 papers identified on decision models for full health economic assessment in obesity, 83% (72 of 87) simulated obesity-associated events. Most of these models simulated CHD (≈83%; 60 of 72), T2D (≈74%; 53 of 72), and stroke (≈65%; 47 of 72).  One key limitation of these models is the lack of published external validation results which could provide valuable information on the predictiveness, and hence on the quality, of their event simulation approaches.  Only ten models performed an external validation and the predictiveness of the event simulation was investigated in a cohort of obese subjects for only one. All others used diabetic or general populations as basis for the validation; consequently no insights on the predictiveness of the applied event simulation approaches in obese subjects could be provided.  Accordingly, one limitation of our (current) findings is that the published models identified do not provide sufficient insights into the quality of the event simulation approach.  In order to investigate the quality of the different methodologies applied we need to perform some additional research steps.  This means that it will be necessary to rebuild/reprogram the key event simulation approaches, feeding the rebuilt models with comparable patient population and intervention effect data and performing an external validation that compares the model-based event simulations to long-term epidemiological observations in the field of obesity.
Results
 In total 4,293 studies were identified via the database searches, 4,304 abstracts were reviewed (database search plus n=11 hand search). Out of these 142 articles selected for full-text review, 87 papers met our inclusion criteria.  Most but not all included models simulated obesity-associated events; of the 87 decision models identified, 72 simulated obesity-associated events, and in the other models the change in BMI was directly transferred into costs and effects (e.g. expressed as quality-adjusted life years).  As shown in Figure 1 , most of these models simulated coronary heart disease (CHD) (≈83%; 60 of 72), type 2 diabetes (T2D) (≈74%; 53 of 72), and stroke (≈65%; 47 of 72). A minority of the models simulated cancer (≈35%), osteoarthritis (≈24%), hyperlipidemia (≈11%), hypertension (≈11%), and peripheral arterial disease (≈10%).
 All other models focused mainly on the external event validation in cohorts of type 2 diabetes patients; which is related to the fact that most of these external validation procedures were performed for the large diabetes models (7 of 10 models), namely the CDC-RTI Diabetes Model (n=3), the Core Diabetes Model (n=2), and the Archimedes Diabetes Model (n=2).  An overview of the ten obesity models for that an external validation was performed is shown in Table 1 .
* The percentages presented above are calculated on the basis of the 72 decision models that simulate obesity-associated events; the 15 remaining decision models that were excluded simulated no events.
 The majority of models simulate more than one event: ≈36% simulate five or more events, ≈25% simulate four events, ≈17% three events, ≈10% two events and ≈12% only one event.  Only ten models (≈15%; 10 of 68) that simulated CHD, T2D and/or stroke, performed an external validation procedure [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , and only for one of those models [17] the predictiveness of the event simulation was investigated in a cohort of obese subjects.
OBJECTIVES:
For assessing the long-term health economic impact of obesity programs, modelling techniques are frequently applied to project obesity-associated clinical events over time. To obtain information on the predictive quality of the applied event simulations, which ensures the acceptance of results from economic evaluations, published external event validation approaches were identified, reviewed and analyzed.
METHODS:
A systematic review was performed in Pubmed and NHSEED to identify decision models for full health economic assessments (HEA) in obesity. For each included study we extracted information on the external event validation approach, using the best practice recommendations of the report on "Model Transparency and Validation" issued by the ISPOR-SMDM Modeling Good Research Practices Task Force.
RESULTS:
We identified 87 papers and 83% (72 of 87) simulated obesity-associated events. Only ten models (≈11%) performed an external validation and only for one the predictiveness of the event simulation was investigated in a cohort of obese subjects (AHEAD study; mean BM 35.9 kg/m). Considering other ISPOR best practice criteria we have found that for none of these external validation cases a systematic identification of suitable data sources was performed, and that a justification of the data source selection, due to predefined criteria, was identified only in three cases. However an adequate result presentation (simulation results provided for each source, presentation of discrepancies, and a qualitative measure on fit) was provided for most external validation cases (≥ eight cases).
CONCLUSIONS:
We found that only a limited number of published decision models for full HEAs in obesity have applied an external event validation. In addition, those who conducted external validation suffers from major limitations including the data source selection process, as only in one case, obesity cohorts were used as basis for the validation procedure. Thus in conclusion published obesity models lack information on the predictive quality of the applied event simulation approaches.
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